Pharma Award - April 12, 2019
Mene Pangalos awarded Prix Galien Greece
Mene Pangalos, EVP and President, Research & Development BioPharmaceuticals at AstraZeneca, was awarded the Prix Galien Award Greece on April 11, 2019. The Prix Galien Award is presented to individuals and organisations who have been instrumental in upgrading the quality of, or even saving the lives of patients through the development of innovative drugs and […]
Pharma Business - April 10, 2019
AstraZeneca’s Lynparza approved in EU
AstraZeneca and MSD have announced that the European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer. “With this approval, Lynparza provides patients throughout the EU with a targeted and oral chemotherapy-free treatment option […]
Clinical Trials - April 4, 2019
Positive results from AstraZeneca’s Fasenra trial
A Phase II trial has demonstrated that Fasenra (benralizumab) can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome (HES). In the randomized phase of the 20-patient trial, the primary efficacy endpoint was the percentage of patients who reduced their absolute blood eosinophil counts by 50% or more at week 12. This was achieved […]
Pharma Business - April 1, 2019
AstraZeneca’s Selumetinib granted Breakthrough Therapy Designation
AstraZeneca and MSD have announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. This designation is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN), […]
Collaboration - March 29, 2019
AstraZeneca and Daiichi Sankyo enter collaboration
The global development and commercialization collaboration agreement with Daiichi Sankyo is for trastuzumab deruxtecan (DS-8201), a antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment. Trastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression. In 2017, trastuzumab deruxtecan was granted […]
Pharma Business - March 26, 2019
AstraZeneca’s Forxiga approved in Europe for type-1 diabetes
It is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes. The European Commission (EC) has approved Forxiga (dapagliflozin) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does not provide adequate […]
